Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Endocrine Therapy for ER-beta Positive TNBC
NCT02089854Phase 4Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2014
- Primary completion
- Apr 2019
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of toremifene and anastrozole in triple-negative breast cancer (TNBC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: disease-free survival at 5 years. Status: unknown.
02
Drugs
toremifeneanastrozole
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02089854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02089854.